Tags

Type your tag names separated by a space and hit enter

Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy.
PLoS One 2012; 7(9):e45182Plos

Abstract

Leber's hereditary optic neuropathy (LHON) is an inherited disease caused by mutations in complex I of the mitochondrial respiratory chain. The disease is characterized by loss of central vision due to retinal ganglion cell (RGC) dysfunction and optic nerve atrophy. Despite progress towards a better understanding of the disease, no therapeutic treatment is currently approved for this devastating disease. Idebenone, a short-chain benzoquinone, has shown promising evidence of efficacy in protecting vision loss and in accelerating recovery of visual acuity in patients with LHON. It was therefore of interest to study suitable LHON models in vitro and in vivo to identify anatomical correlates for this protective activity. At nanomolar concentrations, idebenone protected the rodent RGC cell line RGC-5 against complex I dysfunction in vitro. Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro. Consequently, we next investigated the protective effect of idebenone in a mouse model of LHON, whereby mitochondrial complex I dysfunction was caused by exposure to rotenone. In this model, idebenone protected against the loss of retinal ganglion cells, reduction in retinal thickness and gliosis. Furthermore, consistent with this protection of retinal integrity, idebenone restored the functional loss of vision in this disease model. These results support the pharmacological activity of idebenone and indicate that idebenone holds potential as an effective treatment for vision loss in LHON patients.

Authors+Show Affiliations

Santhera Pharmaceuticals, Liestal, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23028832

Citation

Heitz, Fabrice D., et al. "Idebenone Protects Against Retinal Damage and Loss of Vision in a Mouse Model of Leber's Hereditary Optic Neuropathy." PloS One, vol. 7, no. 9, 2012, pp. e45182.
Heitz FD, Erb M, Anklin C, et al. Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PLoS ONE. 2012;7(9):e45182.
Heitz, F. D., Erb, M., Anklin, C., Robay, D., Pernet, V., & Gueven, N. (2012). Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PloS One, 7(9), pp. e45182. doi:10.1371/journal.pone.0045182.
Heitz FD, et al. Idebenone Protects Against Retinal Damage and Loss of Vision in a Mouse Model of Leber's Hereditary Optic Neuropathy. PLoS ONE. 2012;7(9):e45182. PubMed PMID: 23028832.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. AU - Heitz,Fabrice D, AU - Erb,Michael, AU - Anklin,Corinne, AU - Robay,Dimitri, AU - Pernet,Vincent, AU - Gueven,Nuri, Y1 - 2012/09/18/ PY - 2012/05/17/received PY - 2012/08/14/accepted PY - 2012/10/3/entrez PY - 2012/10/3/pubmed PY - 2013/3/1/medline SP - e45182 EP - e45182 JF - PloS one JO - PLoS ONE VL - 7 IS - 9 N2 - Leber's hereditary optic neuropathy (LHON) is an inherited disease caused by mutations in complex I of the mitochondrial respiratory chain. The disease is characterized by loss of central vision due to retinal ganglion cell (RGC) dysfunction and optic nerve atrophy. Despite progress towards a better understanding of the disease, no therapeutic treatment is currently approved for this devastating disease. Idebenone, a short-chain benzoquinone, has shown promising evidence of efficacy in protecting vision loss and in accelerating recovery of visual acuity in patients with LHON. It was therefore of interest to study suitable LHON models in vitro and in vivo to identify anatomical correlates for this protective activity. At nanomolar concentrations, idebenone protected the rodent RGC cell line RGC-5 against complex I dysfunction in vitro. Consistent with the reported dosing and observed effects in LHON patients, we describe that in mice, idebenone penetrated into the eye at concentrations equivalent to those which protected RGC-5 cells from complex I dysfunction in vitro. Consequently, we next investigated the protective effect of idebenone in a mouse model of LHON, whereby mitochondrial complex I dysfunction was caused by exposure to rotenone. In this model, idebenone protected against the loss of retinal ganglion cells, reduction in retinal thickness and gliosis. Furthermore, consistent with this protection of retinal integrity, idebenone restored the functional loss of vision in this disease model. These results support the pharmacological activity of idebenone and indicate that idebenone holds potential as an effective treatment for vision loss in LHON patients. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/23028832/Idebenone_protects_against_retinal_damage_and_loss_of_vision_in_a_mouse_model_of_Leber's_hereditary_optic_neuropathy_ L2 - http://dx.plos.org/10.1371/journal.pone.0045182 DB - PRIME DP - Unbound Medicine ER -